Leading biosimilars Lek, a Sandoz company, is the largest provider of biosimilar medicines, with ongoing expansion and a new biosimilar facility investment in Slovenia. This presents opportunities to package, co-develop, or supply biosimilar pipelines to global markets and leverage their manufacturing capacity.

Expansion momentum Recent and planned facility expansions in Slovenia, including a US$440M biosimilar facility and production capacity growth, indicate increased manufacturing output and potential for scalable partnerships, contract manufacturing, and supply agreements.

Global markets Lek supplies nearly 60 markets and contributes to international healthcare with affordable medicines. There is opportunity to offer distribution, regulatory, and market access support, as well as licensing or co-promotion deals in emerging markets.

Strong local footprint Slovenia accounts for a notable share of GDP and Lek is a top employer with a long history of collaboration with the Slovenian research ecosystem. Opportunities exist for public-private partnerships, local supply-chain resilience programs, and academic-industry collaborations to accelerate product development.

Innovation financing The company invests over €100 million annually in development and is a leading development center for technologically complex projects. This signals openness to partnerships in R&D funding, joint ventures, and technology licensing to accelerate new generics, biosimilars, and APIs.